Quick Answer
NORTHWEST BIOTHERAPEUTICS INC reported R&D Expense of $34.89 million for fiscal year 2024.
NORTHWEST BIOTHERAPEUTICS INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $34.89M | +25.8% |
| 2023 | $27.73M | -21.9% |
| 2022 | $35.51M | +74.9% |
| 2021 | $20.31M | -39.6% |
| 2020 | $33.64M | +138.5% |
| 2019 | $14.11M | -22.3% |
| 2018 | $18.15M | -45.8% |
| 2017 | $33.52M | +90481.1% |
| 2017 | $37.0K | -99.9% |
| 2016 | $60.08M | -41.7% |
| 2015 | $103.12M | +20.4% |
| 2014 | $85.64M | +95.0% |
| 2013 | $43.91M | +51.9% |
| 2012 | $28.91M | +114.9% |
| 2011 | $13.45M | +35.9% |
| 2010 | $9.90M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.45M | -8.4% | +0.3% |
| June 30, 2025 | $7.43M | -10.4% | -11.0% |
| March 31, 2025 | $8.35M | +5.1% | +2.7% |
| September 30, 2024 | $8.13M | +12.9% | -2.0% |
| June 30, 2024 | $8.29M | +33.5% | +4.4% |
| March 31, 2024 | $7.94M | +15.8% | +10.3% |
| September 30, 2023 | $7.20M | -6.4% | +15.9% |
| June 30, 2023 | $6.21M | -54.5% | -9.4% |
- NORTHWEST BIOTHERAPEUTICS INC showed an increase of +25.8% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2024 period, NORTHWEST BIOTHERAPEUTICS INC’s r&d expense has grown by 252.4% (from $9.90 million to $34.89 million).
- The most recent figure is from NORTHWEST BIOTHERAPEUTICS INC’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: